June 26, 2023
1 min watch
Save
VIDEO: Extended-durability agents changing the landscape of retinal diseases
Key takeaways:
- In the retina space, there is a need for more durable agents to decrease the burden of repeated injections.
- Some of these agents are available now, while others are nearing approval.
KIAWAH ISLAND, S.C. — In this Healio Video Perspective from Kiawah Eye, Rishi P. Singh, MD, summarizes the content of his presentation on emerging therapies for retinal diseases.
“We need better durable agents, we need better drying agents, and we certainly want to decrease the burden for our patients of all of these injections,” he said.
The newly approved or close-to-approval agents include faricimab, the first bispecific molecule targeting the angiopoietin-2 and VEGF pathways together; high-dose aflibercept with better drying effect and extended durability; and sustained-release corticosteroids.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Singh reports consulting for Alcon, Apellis, AsclepiX, Bausch + Lomb, Genentech, Gyroscope, Iveric Bio, Novartis and Regeneron.
Read more about